CN111094547B - 用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法 - Google Patents
用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法 Download PDFInfo
- Publication number
- CN111094547B CN111094547B CN201880038434.7A CN201880038434A CN111094547B CN 111094547 B CN111094547 B CN 111094547B CN 201880038434 A CN201880038434 A CN 201880038434A CN 111094547 B CN111094547 B CN 111094547B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- pancreatic progenitor
- progenitor cells
- pancreatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 210000001671 embryonic stem cell Anatomy 0.000 title claims abstract description 58
- 210000001900 endoderm Anatomy 0.000 title claims description 43
- 210000004039 endoderm cell Anatomy 0.000 title description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 423
- 210000000130 stem cell Anatomy 0.000 claims abstract description 155
- 102100024209 CD177 antigen Human genes 0.000 claims abstract description 147
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 claims abstract description 147
- 239000003550 marker Substances 0.000 claims abstract description 29
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims abstract description 26
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 85
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 85
- 239000003446 ligand Substances 0.000 claims description 76
- 230000014509 gene expression Effects 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 39
- 230000005291 magnetic effect Effects 0.000 claims description 33
- 239000002458 cell surface marker Substances 0.000 claims description 30
- 238000003753 real-time PCR Methods 0.000 claims description 30
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 claims description 24
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 claims description 24
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 claims description 21
- 102100030243 Transcription factor SOX-17 Human genes 0.000 claims description 21
- 238000000684 flow cytometry Methods 0.000 claims description 17
- 239000011324 bead Substances 0.000 claims description 16
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 11
- 102100025745 Cerberus Human genes 0.000 claims description 10
- 101000914195 Homo sapiens Cerberus Proteins 0.000 claims description 10
- 238000001042 affinity chromatography Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 102100034980 ICOS ligand Human genes 0.000 abstract description 90
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 abstract description 85
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 59
- 102100022337 Integrin alpha-V Human genes 0.000 abstract description 30
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 abstract description 28
- 210000004185 liver Anatomy 0.000 abstract description 19
- 230000004069 differentiation Effects 0.000 description 78
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 56
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 40
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 239000002609 medium Substances 0.000 description 38
- 230000002440 hepatic effect Effects 0.000 description 36
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 description 30
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 description 30
- 102000004877 Insulin Human genes 0.000 description 29
- 108090001061 Insulin Proteins 0.000 description 29
- 102000013814 Wnt Human genes 0.000 description 29
- 108050003627 Wnt Proteins 0.000 description 29
- 229940125396 insulin Drugs 0.000 description 28
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 26
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 description 25
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 25
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 21
- 238000011002 quantification Methods 0.000 description 21
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 230000011664 signaling Effects 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 230000006698 induction Effects 0.000 description 14
- 238000007898 magnetic cell sorting Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 108060000903 Beta-catenin Proteins 0.000 description 11
- 102000015735 Beta-catenin Human genes 0.000 description 11
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 description 11
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 description 11
- 210000003372 endocrine gland Anatomy 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 101000979205 Homo sapiens Transcription factor MafA Proteins 0.000 description 9
- 102100023237 Transcription factor MafA Human genes 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000003125 immunofluorescent labeling Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 8
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 8
- 108091006296 SLC2A1 Proteins 0.000 description 8
- 102000044880 Wnt3A Human genes 0.000 description 8
- 108700013515 Wnt3A Proteins 0.000 description 8
- 108010023082 activin A Proteins 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 230000031712 Wnt receptor signaling pathway, planar cell polarity pathway Effects 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 101150068520 wnt3a gene Proteins 0.000 description 7
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 6
- 102100038553 Neurogenin-3 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000007640 basal medium Substances 0.000 description 6
- 210000002304 esc Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 238000000059 patterning Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 5
- 101710093458 ICOS ligand Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000153 supplemental effect Effects 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- 238000011870 unpaired t-test Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 4
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 4
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 4
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 4
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 description 4
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000015031 pancreas development Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- FOORCIAZMIWALX-ULJHMMPZSA-N (z)-n-(4-benzylpiperazin-1-yl)-1-(3,5-dimethyl-1-phenylpyrazol-4-yl)methanimine Chemical compound CC1=NN(C=2C=CC=CC=2)C(C)=C1\C=N/N(CC1)CCN1CC1=CC=CC=C1 FOORCIAZMIWALX-ULJHMMPZSA-N 0.000 description 3
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 3
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 3
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 3
- 101000738523 Homo sapiens Pancreas transcription factor 1 subunit alpha Proteins 0.000 description 3
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 3
- 101000939387 Homo sapiens Urocortin-3 Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 3
- 101100519293 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pdx-1 gene Proteins 0.000 description 3
- 102100037878 Pancreas transcription factor 1 subunit alpha Human genes 0.000 description 3
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 3
- 102100029794 Urocortin-3 Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002122 magnetic nanoparticle Substances 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 101100317380 Danio rerio wnt4a gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 2
- 101000867466 Homo sapiens Segment polarity protein dishevelled homolog DVL-2 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 101150111723 PDX1 gene Proteins 0.000 description 2
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100032753 Segment polarity protein dishevelled homolog DVL-2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 101150010310 WNT-4 gene Proteins 0.000 description 2
- 102000052548 Wnt-4 Human genes 0.000 description 2
- 108700020984 Wnt-4 Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000009996 pancreatic endocrine effect Effects 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DJBRKGZFUXKLKO-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical class Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 101150047960 GCG gene Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000576323 Homo sapiens Motor neuron and pancreas homeobox protein 1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010040765 Integrin alphaV Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102100025170 Motor neuron and pancreas homeobox protein 1 Human genes 0.000 description 1
- 101100460498 Mus musculus Nkx2-2 gene Proteins 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000052651 Pancreatic hormone Human genes 0.000 description 1
- 108700020479 Pancreatic hormone Proteins 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 102000012850 Patched-1 Receptor Human genes 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000014104 Transcription factor MafA Human genes 0.000 description 1
- 108050003977 Transcription factor MafA Proteins 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 108091008108 affimer Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- -1 capture media Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033081 cell fate specification Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000007120 differential activation Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 108700011804 pancreatic and duodenal homeobox 1 Proteins 0.000 description 1
- 229940032957 pancreatic hormone Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU100320 | 2017-06-14 | ||
| LU100320 | 2017-06-14 | ||
| PCT/EP2018/065779 WO2018229179A1 (en) | 2017-06-14 | 2018-06-14 | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111094547A CN111094547A (zh) | 2020-05-01 |
| CN111094547B true CN111094547B (zh) | 2024-02-09 |
Family
ID=59686996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880038434.7A Active CN111094547B (zh) | 2017-06-14 | 2018-06-14 | 用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210147807A1 (ja) |
| EP (1) | EP3638774A1 (ja) |
| JP (1) | JP7145209B2 (ja) |
| CN (1) | CN111094547B (ja) |
| WO (1) | WO2018229179A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6954711B2 (ja) | 2015-04-24 | 2021-10-27 | ユニバーシティ オブ コペンハーゲン | 真正膵臓前駆細胞の単離 |
| EP3638774A1 (en) * | 2017-06-14 | 2020-04-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| CA2983845C (en) | 2017-10-26 | 2024-01-30 | University Of Copenhagen | Generation of glucose-responsive beta cells |
| US20210283565A1 (en) | 2020-03-10 | 2021-09-16 | Cellares Corporation | Systems and methods for cell processing |
| CN113234664B (zh) * | 2021-05-11 | 2024-05-10 | 澳门大学 | 一种胰腺祖细胞的制备方法及其应用 |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001023554A1 (de) * | 1999-09-30 | 2001-04-05 | Universitätsklinikum Freiburg | Das gen prv-1 und dessen verwendung |
| KR20080068394A (ko) * | 2007-01-19 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 췌장 베타세포로의 분화능을 가지는 성체 줄기세포 |
| WO2009131568A1 (en) * | 2008-04-21 | 2009-10-29 | Cythera, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| TW201009077A (en) * | 2008-08-27 | 2010-03-01 | Taipei Veterans General Hospital | Isolation and cultivation system for normal or tumorigenic stem cell |
| WO2012070014A2 (en) * | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| WO2014030166A1 (en) * | 2012-08-22 | 2014-02-27 | Yeda Research And Development Co. Ltd. | Methods of isolating distinct pancreatic cell types |
| CN104284977A (zh) * | 2012-05-07 | 2015-01-14 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内胚层的分化 |
| CN104334719A (zh) * | 2012-06-08 | 2015-02-04 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌细胞的分化 |
| AU2015200985A1 (en) * | 2008-04-21 | 2015-03-19 | Viacyte, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| CN104755607A (zh) * | 2012-09-20 | 2015-07-01 | 剑桥企业有限公司 | 多能哺乳动物细胞的体外胰腺分化 |
| CN107787363A (zh) * | 2015-04-24 | 2018-03-09 | 哥本哈根大学 | 真正的胰腺祖细胞的分离 |
| CN108472281A (zh) * | 2015-12-18 | 2018-08-31 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 用于治疗铜相关疾病的手段和方法 |
| CN109069870A (zh) * | 2016-02-24 | 2018-12-21 | 洛克菲勒大学 | 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选系统、模型及它们的应用 |
| CN109154004A (zh) * | 2016-01-12 | 2019-01-04 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 用于治疗hbv的手段和方法 |
| CN112980771A (zh) * | 2021-03-05 | 2021-06-18 | 盛泰英诺(嘉兴)医疗科技有限公司 | 一种制备胰腺beta细胞的方法及其应用 |
| CN115461446A (zh) * | 2020-04-28 | 2022-12-09 | 加利福尼亚大学董事会 | 用于在体外生成胸腺细胞的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335181C (en) | 1988-10-11 | 1995-04-11 | R. Alan Hardwick | System for selective cell separation from cell concentrate |
| AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| JP2005510232A (ja) | 2001-11-26 | 2005-04-21 | アドバンスド セル テクノロジー、インク． | 再プログラムされたヒト体細胞核ならびに自系および同系なヒト幹細胞の製造および使用方法 |
| US20060029987A1 (en) * | 2004-08-06 | 2006-02-09 | Applera Corporation | Diagnosis of pancreatic cancer by using pancreatic targets |
| US20060035239A1 (en) * | 2004-08-06 | 2006-02-16 | Applera Corporation | Method and compositions for treating diseases targeting CD51 |
| ES2640216T3 (es) | 2007-12-07 | 2017-11-02 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
| US8338170B2 (en) | 2008-04-21 | 2012-12-25 | Viacyte, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| GB2506936A (en) | 2012-10-15 | 2014-04-16 | Innovia Films Ltd | Birefringence authentication apparatus and method |
| EP3638774A1 (en) * | 2017-06-14 | 2020-04-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| US20190128885A1 (en) * | 2017-07-25 | 2019-05-02 | University Health Network | Selection of pancreatic progenitors |
-
2018
- 2018-06-14 EP EP18736809.7A patent/EP3638774A1/en active Pending
- 2018-06-14 CN CN201880038434.7A patent/CN111094547B/zh active Active
- 2018-06-14 WO PCT/EP2018/065779 patent/WO2018229179A1/en unknown
- 2018-06-14 JP JP2020519844A patent/JP7145209B2/ja active Active
- 2018-06-14 US US16/622,825 patent/US20210147807A1/en active Pending
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001023554A1 (de) * | 1999-09-30 | 2001-04-05 | Universitätsklinikum Freiburg | Das gen prv-1 und dessen verwendung |
| KR20080068394A (ko) * | 2007-01-19 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 췌장 베타세포로의 분화능을 가지는 성체 줄기세포 |
| AU2015200985A1 (en) * | 2008-04-21 | 2015-03-19 | Viacyte, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| WO2009131568A1 (en) * | 2008-04-21 | 2009-10-29 | Cythera, Inc. | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
| TW201009077A (en) * | 2008-08-27 | 2010-03-01 | Taipei Veterans General Hospital | Isolation and cultivation system for normal or tumorigenic stem cell |
| WO2012070014A2 (en) * | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| CN104284977A (zh) * | 2012-05-07 | 2015-01-14 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内胚层的分化 |
| CN104334719A (zh) * | 2012-06-08 | 2015-02-04 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌细胞的分化 |
| WO2014030166A1 (en) * | 2012-08-22 | 2014-02-27 | Yeda Research And Development Co. Ltd. | Methods of isolating distinct pancreatic cell types |
| CN104583392A (zh) * | 2012-08-22 | 2015-04-29 | 耶达研究与发展有限公司 | 分离不同胰腺细胞类型的方法 |
| CN104755607A (zh) * | 2012-09-20 | 2015-07-01 | 剑桥企业有限公司 | 多能哺乳动物细胞的体外胰腺分化 |
| CN107787363A (zh) * | 2015-04-24 | 2018-03-09 | 哥本哈根大学 | 真正的胰腺祖细胞的分离 |
| CN108472281A (zh) * | 2015-12-18 | 2018-08-31 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 用于治疗铜相关疾病的手段和方法 |
| CN109154004A (zh) * | 2016-01-12 | 2019-01-04 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） | 用于治疗hbv的手段和方法 |
| CN109069870A (zh) * | 2016-02-24 | 2018-12-21 | 洛克菲勒大学 | 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选系统、模型及它们的应用 |
| CN115461446A (zh) * | 2020-04-28 | 2022-12-09 | 加利福尼亚大学董事会 | 用于在体外生成胸腺细胞的方法 |
| CN112980771A (zh) * | 2021-03-05 | 2021-06-18 | 盛泰英诺(嘉兴)医疗科技有限公司 | 一种制备胰腺beta细胞的方法及其应用 |
| WO2022183740A1 (zh) * | 2021-03-05 | 2022-09-09 | 贝康医学科技有限公司 | 一种制备胰腺beta细胞的方法及其应用 |
Non-Patent Citations (5)
| Title |
|---|
| New markers for tracking endoderm induction and hepatocyte differentiation from human pluripotent stem cells;Audrey Holtzinger等;STEM CELLS AND REGENERATION;第4253-4256页 * |
| Xin Cheng等.Self-Renewing Endodermal Progenitor Lines Generated from Human Pluripotent Stem Cells.Cell Stem Cell.2012,第371-384页. * |
| 张勇 ; 赵建宁 ; .脂肪干细胞的研究进展.医学研究生学报.2009,(第10期),第1-6页. * |
| 戴鹏秀.脂肪间充质干细胞重编程为胰岛β-细胞治疗犬糖尿病研究.中国博士学位论文全文数据库农业科技辑.2022,B050-95. * |
| 脂肪源性干细胞的定向分化潜能及临床应用前景;王伟;撒亚莲;严新民;;中华临床医师杂志(电子版)(第02期);第153-156页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111094547A (zh) | 2020-05-01 |
| JP7145209B2 (ja) | 2022-09-30 |
| JP2020524525A (ja) | 2020-08-20 |
| US20210147807A1 (en) | 2021-05-20 |
| WO2018229179A1 (en) | 2018-12-20 |
| EP3638774A1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111094547B (zh) | 用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法 | |
| US10266808B2 (en) | Method of enriching for pancreatic endocrine cells that express chromogranin A | |
| Drukker et al. | Isolation of primitive endoderm, mesoderm, vascular endothelial and trophoblast progenitors from human pluripotent stem cells | |
| EP2283117B1 (en) | Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells | |
| CN107189979B (zh) | 纯化衍生自多能干细胞的细胞的方法 | |
| CN107787363B (zh) | 真正的胰腺祖细胞的分离 | |
| US20210246428A1 (en) | Cell populations and gene expression associated with in vitro beta cell differentiation | |
| AU2015200985B2 (en) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells | |
| AU2016203724B2 (en) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells | |
| AU2017276263B2 (en) | Methods for enriching primitive gut tube |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |